Related references
Note: Only part of the references are listed.Biochemical Activity of Vaborbactam
Ruslan Tsivkovski et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Beyond Piperacillin-Tazobactam: Cefepime and AAI101 as a Potent β-Lactam - β-Lactamase Inhibitor Combination
Krisztina M. Papp-Wallace et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Structural Insights into the Inhibition of the Extended-Spectrum β-Lactamase PER-2 by Avibactam
Melina Ruggiero et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Nacubactam Enhances Meropenem Activity against Carbapenem-Resistant Klebsiella pneumoniae Producing KPC
Melissa D. Barnes et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Switching Partners: Piperacillin-Avibactam Is a Highly Potent Combination against Multidrug-Resistant Burkholderia cepacia Complex and Burkholderia gladioli Cystic Fibrosis Isolates
Elise T. Zeiser et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2019)
The latest advances in β-lactam/β-lactamase inhibitor combinations for the treatment of Gram-negative bacterial infections
Krisztina M. Papp-Wallace
EXPERT OPINION ON PHARMACOTHERAPY (2019)
Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix
Dorothee Liebschner et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2019)
Sequence heterogeneity of the PenA carbapenemase in clinical isolates of Burkholderia multivorans
Scott A. Becka et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2018)
Exploring the Role of the Ω-Loop in the Evolution of Ceftazidime Resistance in the PenA β-Lactamase from Burkholderia multivorans, an Important Cystic Fibrosis Pathogen
Krisztina M. Papp-Wallace et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Overcoming an Extremely Drug Resistant (XDR) Pathogen: Avibactam Restores Susceptibility to Ceftazidime for Burkholderia cepacia Complex Isolates from Cystic Fibrosis Patients
Krisztina M. Papp-Wallace et al.
ACS INFECTIOUS DISEASES (2017)
New Delhi Metallo-β-Lactamase 1 Catalyzes Avibactam and Aztreonam Hydrolysis
Christopher T. Lohans et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Impact of Mutations at Arg220 and Thr237 in PER-2 β-Lactamase on Conformation, Activity, and Susceptibility to Inhibitors
Melina Ruggiero et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Influence of Precipitants on Molecular Arrangements and Space Groups of Protein Crystals
Satoshi Fudo et al.
CRYSTAL GROWTH & DESIGN (2017)
Interaction of Avibactam with Class B Metallo-β-Lactamases
Martine I. Abboud et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Removal of the Side Chain at the Active-Site Serine by a Glycine Substitution Increases the Stability of a Wide Range of Serine β-Lactamases by Relieving Steric Strain
Vlatko Stojanoski et al.
BIOCHEMISTRY (2016)
Two Distinctive Binding Modes of Endonuclease Inhibitors to the N-Terminal Region of Influenza Virus Polymerase Acidic Subunit
Satoshi Fudo et al.
BIOCHEMISTRY (2016)
Investigations on recyclisation and hydrolysis in avibactam mediated serine beta-lactamase inhibition
Hwanho Choi et al.
ORGANIC & BIOMOLECULAR CHEMISTRY (2016)
Variants of β-Lactamase KPC-2 That Are Resistant to Inhibition by Avibactam
Krisztina M. Papp-Wallace et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB
James A. Maier et al.
JOURNAL OF CHEMICAL THEORY AND COMPUTATION (2015)
Kinetics of Avibactam Inhibition against Class A, C, and D β-Lactamases
David E. Ehmann et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Insights into β-Lactamases from Burkholderia Species, Two Phylogenetically Related yet Distinct Resistance Determinants
Krisztina M. Papp-Wallace et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Routine Microsecond Molecular Dynamics Simulations with AMBER on GPUs. 2. Explicit Solvent Particle Mesh Ewald
Romelia Salomon-Ferrer et al.
JOURNAL OF CHEMICAL THEORY AND COMPUTATION (2013)
Design and Exploration of Novel Boronic Acid Inhibitors Reveals Important Interactions with a Clavulanic Acid-Resistant Sulfhydryl-Variable (SHV) β-Lactamase
Marisa L. Winkler et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Understanding the Molecular Determinants of Substrate and Inhibitor Specificities in the Carbapenemase KPC-2: Exploring the Roles of Arg220 and Glu276
Krisztina M. Papp-Wallace et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Placevent: An algorithm for prediction of explicit solvent atom distributionuApplication to HIV-1 protease and F-ATP synthase
Daniel J. Sindhikara et al.
JOURNAL OF COMPUTATIONAL CHEMISTRY (2012)
Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor
David E. Ehmann et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
XDS
Wolfgang Kabsch
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY (2010)
Features and development of Coot
P. Emsley et al.
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY (2010)
Inhibitor Resistance in the KPC-2 β-Lactamase, a Preeminent Property of This Class A β-Lactamase
Krisztina M. Papp-Wallace et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Three Decades of beta-Lactamase Inhibitors
Sarah M. Drawz et al.
CLINICAL MICROBIOLOGY REVIEWS (2010)
Elucidating the role of Trp105 in the KPC-2 β-lactamase
Krisztina M. Papp-Wallace et al.
PROTEIN SCIENCE (2010)
IRT and CMT beta-lactamases and inhibitor resistance
R. Canton et al.
CLINICAL MICROBIOLOGY AND INFECTION (2008)
Validation studies of the site-directed docking program LibDock
Shashidhar N. Rao et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2007)
Probing active site chemistry in SHV β-lactamase variants at ambler position 244 -: Understanding unique properties of inhibitor resistance
Jodi M. Thomson et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
TEM-121, a novel complex mutant of TEM-type β-lactamase from Enterobacter aerogenes
L Poirel et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Kinases, homology models, and high throughput docking
DJ Diller et al.
JOURNAL OF MEDICINAL CHEMISTRY (2003)